Cangrelor
Cangrelor
Cangrelor (/kænˈɡrɛlɔːr/) is an antiplatelet agent used to reduce the risk of percutaneous coronary intervention (PCI) related complications such as stent thrombosis in patients undergoing PCI.
Etymology
The name "Cangrelor" is derived from the chemical name of the drug, which is a P2Y12 receptor antagonist. The "Cang" part of the name is derived from the chemical structure of the drug, which contains a cangrelor moiety.
Usage
Cangrelor is used in patients undergoing PCI who have not been treated with a P2Y12 platelet inhibitor and are not able to take oral P2Y12 platelet inhibitors. It is administered intravenously during the procedure to prevent platelet aggregation and reduce the risk of stent thrombosis.
Related Terms
- Antiplatelet agent: A type of drug that decreases platelet aggregation and inhibits thrombus formation.
- Percutaneous coronary intervention: A non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart.
- Stent thrombosis: A serious complication that can occur after a stent, a small mesh tube that's used to treat narrow or weak arteries, is placed in a coronary artery.
- P2Y12 receptor: A protein that in humans is encoded by the P2RY12 gene. It belongs to the group of G protein-coupled receptors. This receptor is also present on the platelet surface and is involved in platelet aggregation.
External links
- Medical encyclopedia article on Cangrelor
- Wikipedia's article - Cangrelor
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski